China NMPA approves Tislelizumab for metastatic nasopharyngeal cancer
Tislelizumab is now approved in nine indications in China
Tislelizumab is now approved in nine indications in China
Tislelizumab is now approved for seven indications in China
 
        Subscribe To Our Newsletter & Stay Updated